The Act curbs US-China biotech collaborations, spurring opportunities for emerging markets in pharma supply chains.
His nomination to head the HHS by President-elect Donald Trump on Thursday could bring sweeping changes to the way Washington, D.C., targets health issues.
The U.S. Treasury Department said on Thursday that New York-based insurer MetLife's unit, American Life Insurance Company, ...
Robert F. Kennedy Jr. has vowed to combat "the chronic disease epidemic in this country" in the Trump administration, with ...
While A.I. promises breakthroughs, industry leaders warn that transparency and patient safety must remain front and center.
Australia’s audit office will probe the Morrison government’s $2 billion deal with US pharmaceutical giant Moderna to set up ...
Teva Pharmaceutical Industries raised its 2024 revenue and earnings guidance on Wednesday after beating third-quarter profit ...
With Donald Trump now confirmed as the President-elect, the life sciences industry is bracing for significant policy shifts that could impact everything from drug pricing to regulatory practices. Trum ...
The Standard & Poor’s Biotechnology Select Industry Index (XBI), one measure of the health of the life sciences industry, ...
A GlobalData analyst has warned that Trump's second term could see major changes in US healthcare, and RFK could rock the ...